硼替佐米：POEMS 综合征的一种新治疗选择。
Bortezomib: a new therapeutic option for POEMS syndrome.
机构信息
Department of Hematology, Marmara University School of Medicine, Marmara University, Istanbul, Turkey.
出版信息
Eur J Haematol. 2010 Feb 1;84(2):175-7. doi: 10.1111/j.1600-0609.2009.01341.x. Epub 2009 Sep 3.
OBJECTIVE
POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated.
METHODS
We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib.
RESULTS
After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically.
CONCLUSION
Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.
目的
POEMS 综合征具有其经典的“五联征”（多发性神经病、脏器肿大、内分泌病、M 蛋白和皮肤改变），是一种罕见的多系统疾病。促炎和促血管生成细胞因子在其发病机制中起重要作用。治疗方案仍存在争议。
方法
我们报告了一例成功应用硼替佐米治疗的 POEMS 综合征患者。
结果
该患者接受七周期硼替佐米治疗后，血清 M 蛋白水平降至正常范围，达到近乎完全缓解。其多发性神经病症状显著改善。
结论
硼替佐米可能是 POEMS 综合征患者的一种有效且安全的治疗选择。
Zotero 插件